About the Company
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NTLA News
Is Intellia Therapeutics Stock a Buy Now?
Unfortunately, Intellia Therapeutics (NASDAQ: NTLA) hasn't been one of the top performers in this niche. The biotech's shares ...
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
Intellia Therapeutics (NASDAQ: NTLA) updated investors with its results for the fourth quarter on Feb. 23, Cannacord Genuity ...
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors
Intellia Therapeutics, Inc. (NTLA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, NTLA broke through the 50-day moving average, ...
Buy Rating Affirmed for Intellia Therapeutics on Strong Clinical Execution and Financial Health
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NTLA stock, giving a Buy rating on February 23. Mani Foroohar ...
What’s The Deal With Intellia Therapeutics Inc (NASDAQ: NTLA)?
Intellia Therapeutics Inc (NASDAQ:NTLA) traded at $27.66 at close of the session on Monday, February 26, made an upward move of 5.98% on its previous day’s price. Looking at the stock we see that its ...
Intellia Therapeutics files patent for genetic modification to reduce HLA-a protein expression in cells
Discover how Intellia Therapeutics Inc. is revolutionizing adoptive cell transfer therapies with patented methods to reduce HLA-A protein expression in engineered human cells. Explore the potential ...
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Terns Pharmaceuticals (TERN – Research ...
Biotech bankruptcies: what to expect in 2024 following a record year?
2023 was a year of economic uncertainty for the biotech industry, which led to a funding drought. It also held the record for ...
Merck completes acquisition of Harpoon Therapeutics
Merck (MSD) has concluded the acquisition of all the outstanding shares of US-based Harpoon Therapeutics to broaden its ...
Bayer pays $310M to buy into BridgeBio heart drug
BridgeBio is now leading a group of other developers, including Alnylam Pharmaceuticals, Ionis Pharmaceuticals and Intellia Therapeutics, that aim to come up with better options. Like Vyndamax, ...
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...
Nasdaq Futures Climb as Nvidia’s Blowout Sales Forecast Boosts Sentiment, U.S. PMI Data in Focus
Detailed price information for Royal Caribbean Cruises Ltd (RCL-N) from The Globe and Mail including charting and trades.
Loading the latest forecasts...